Actos (Pioglitazone) Manufacturer Copay Program: How to Get Pioglitazone at the Lowest Cost

Why Brand-Name Actos Copay Cards No Longer Exist

Takeda Pharmaceuticals launched Actos (pioglitazone) in 1999 and held U.S. patent protection until August 2012. The manufacturer copay card program that once reduced brand Actos copays to $0 to $25 per fill was tied to that exclusivity window. Once generic pioglitazone entered the market, Takeda discontinued the branded copay assistance card because payers and pharmacy benefit managers shifted prescriptions to the generic automatically.

This is not unusual. Manufacturer copay programs exist primarily to keep patients on brand products when cheaper alternatives threaten market share. A 2021 analysis in JAMA Internal Medicine found that copay coupon use delayed generic substitution by an average of 2.4 months across 23 drug classes, costing the U.S. health system an estimated $2.2 billion annually (1). Once patent protection lapses and generics saturate the market, the financial rationale for copay cards disappears.

The practical result for patients in 2026 is straightforward. Generic pioglitazone 15 mg, 30 mg, and 45 mg tablets are manufactured by Teva, Mylan (Viatris), Sun Pharma, Aurobindo, and others. Competition among these manufacturers has driven cash prices to $4 to $15 per month, which is less than what most brand copay cards used to offer (2).

If your pharmacy is still dispensing brand Actos and you are paying a brand-tier copay, ask your pharmacist to substitute the generic. Every state except one permits automatic generic substitution for AB-rated products, and pioglitazone carries an AB rating from the FDA.

What Takeda Patient Assistance Still Covers

Takeda's patient assistance program (TAP, also known as Takeda Help at Hand) remains active in 2026 for patients who are uninsured, underinsured, or meet income thresholds. This is different from a copay card. Patient assistance programs provide free medication directly from the manufacturer, bypassing pharmacy and insurance channels entirely.

Eligibility typically requires a household income at or below 300% of the federal poverty level. For a single adult in 2026, that threshold is approximately $47,520 based on current HHS poverty guidelines (3). Patients apply through their prescriber, and approved applicants receive a 90-day supply shipped to the physician's office or directly to the home.

The American Diabetes Association's Standards of Care (2024) explicitly recommends that clinicians "assess financial barriers to medication adherence and connect patients with manufacturer assistance programs, state pharmaceutical assistance programs, or community health resources" (4). This recommendation reflects a clinical reality. Cost-related nonadherence affects roughly 25% of adults with type 2 diabetes in the United States, according to CDC National Health Interview Survey data (5).

Patients who do not qualify for TAP but still face affordability barriers have other options. The 340B Drug Pricing Program, available through federally qualified health centers, provides pioglitazone at a ceiling price that is typically 50% to 80% below wholesale acquisition cost. Patients do not need to apply separately. They just need to receive care at a 340B-eligible facility.

Generic Pioglitazone Pricing: A Pharmacy-by-Pharmacy Breakdown

The average cash price for a 30-day supply of generic pioglitazone 30 mg (the most commonly prescribed dose) ranges from $4 to $15 depending on the pharmacy. Here is what patients can expect at major chains without insurance.

Walmart and Sam's Club include pioglitazone on their $4 generic list for a 30-day supply and $10 for a 90-day supply. Costco, which does not require a membership for pharmacy purchases, prices generic pioglitazone between $5 and $8 for 30 tablets. CVS, Walgreens, and Rite Aid price the drug between $10 and $20 at cash pay, but free discount cards from GoodRx, RxSaver, or SingleCare can reduce that range to $3 to $9.

These prices make pioglitazone one of the most affordable oral diabetes medications on the market. By comparison, brand-name SGLT2 inhibitors like Jardiance (empagliflozin) still carry a wholesale acquisition cost above $550 per month, and even with manufacturer copay cards, insured patients often pay $10 to $50 per fill (6).

The PROactive trial (N=5,238) demonstrated that pioglitazone reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% in patients with type 2 diabetes and macrovascular disease (HR 0.84, 95% CI 0.72 to 0.98, P=0.027) (7). The IRIS trial (N=3,876) later showed a 24% relative risk reduction in stroke or myocardial infarction among insulin-resistant patients without diabetes (HR 0.76, 95% CI 0.62 to 0.93, P=0.007) (8). At $4 per month, few diabetes drugs offer this much clinical evidence per dollar spent.

How Insurance Plans Cover Pioglitazone in 2026

Generic pioglitazone sits on Tier 1 (preferred generic) of virtually every commercial and Medicare Part D formulary in the United States. Tier 1 placement means the lowest possible copay, typically $0 to $11 for commercial plans and $0 to $10 for Medicare Part D.

The Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 beginning in 2025, with monthly payment smoothing available (9). For a drug that already costs $4 to $15 per month at cash pay, this cap is unlikely to be relevant. But patients taking pioglitazone alongside more expensive medications (GLP-1 receptor agonists, insulin) benefit from the aggregate cap.

Medicaid coverage is universal for pioglitazone across all 50 states. The Medicaid Drug Rebate Program requires manufacturers to provide rebates that bring net costs well below wholesale, and states cannot restrict access to FDA-approved diabetes medications on their preferred drug lists without offering a clinical exception process (10).

For patients with high-deductible health plans (HDHPs), pioglitazone qualifies as a preventive drug under IRS Notice 2019-45, which allows HDHPs to cover certain chronic disease medications before the deductible is met. Pioglitazone is listed explicitly in the preventive drug category for type 2 diabetes (11).

This means a patient on a $3,000-deductible HDHP can receive pioglitazone at the plan's generic copay from day one. Not every HDHP has adopted this provision, so patients should confirm with their plan. But the IRS authorization is in place, and major insurers including Aetna, UnitedHealthcare, and Cigna have adopted it.

Pioglitazone-Metformin Combinations and Cost Implications

The fixed-dose combination of pioglitazone and metformin (formerly marketed as Actoplus Met and Actoplus Met XR) is available as a generic. This tablet combines pioglitazone 15 mg or 30 mg with metformin 500 mg or 850 mg in a single pill.

Generic pioglitazone-metformin costs between $15 and $40 per month depending on the pharmacy, which is modestly more than buying generic pioglitazone and generic metformin separately ($4 each at Walmart). The combination may improve adherence for patients who struggle with pill burden, but it offers no pharmacological advantage over the two drugs taken individually.

The American Diabetes Association's 2024 Standards of Care recommends metformin as first-line pharmacotherapy for most patients with type 2 diabetes, with pioglitazone as a reasonable second-line agent, particularly when cost is a dominant concern or when SGLT2 inhibitors and GLP-1 receptor agonists are not accessible (4). Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Cost remains one of the most significant barriers to diabetes management. We must ensure that effective, evidence-based therapies remain accessible regardless of a patient's insurance status."

Prescribers should be aware that some pharmacy benefit managers apply quantity limits to the combination product that do not apply to the individual components. If a prior authorization is required for pioglitazone-metformin, prescribing the two generics separately eliminates that barrier.

State Pharmaceutical Assistance Programs (SPAPs)

Twenty-seven U.S. states operate pharmaceutical assistance programs that supplement Medicare Part D or provide standalone drug coverage for low-income residents. These programs vary widely in eligibility criteria and benefit design, but nearly all cover generic pioglitazone.

Notable examples include New York's EPIC program, which covers residents aged 65 and older with incomes up to $75,000 (single) or $100,000 (married), and Pennsylvania's PACE/PACENET program for residents 65 and older with incomes up to $33,500 (single) (12). Both programs reduce generic copays to $6 to $9 or less.

The National Council on Aging's BenefitsCheckUp tool (benefitscheckup.org) screens patients for eligibility across SPAPs, Extra Help (Medicare Low-Income Subsidy), and manufacturer assistance simultaneously. Clinicians or care coordinators can complete the screening in under five minutes.

For uninsured patients who do not qualify for Medicaid, SPAPs, or manufacturer assistance, community health centers receiving Section 330 federal funding are required to provide care on a sliding fee scale. Pioglitazone dispensed through a 340B-eligible pharmacy at these centers may cost $0 to $4 per fill.

When Brand Actos Might Still Be Dispensed

In rare situations, a prescriber may write "brand medically necessary" for Actos rather than generic pioglitazone. This can occur when a patient reports adverse effects specific to a generic formulation (differences in inactive ingredients, binders, or dye sensitivity) or when a prescriber suspects variable bioavailability.

The FDA considers all AB-rated generics therapeutically equivalent to the reference listed drug, meaning they are expected to produce the same clinical effect and safety profile (2). However, the Endocrine Society and the American Association of Clinical Endocrinology (AACE) acknowledge that individual patient responses to generic substitutions can vary, particularly with narrow therapeutic index drugs. Pioglitazone is not classified as a narrow therapeutic index drug, so these cases are uncommon.

If brand Actos is medically necessary, the cash price runs $350 to $450 per month. Insurance coverage will depend on the plan's formulary. Most commercial plans require a step therapy fail on the generic before covering the brand, and the patient will likely be placed on a Tier 3 (non-preferred brand) with a $40 to $80 copay.

Patients in this situation should contact Takeda's patient assistance line directly (1-800-830-9159) to ask about any active bridge or replacement programs. Programs change frequently, so verifying current availability before each refill cycle is appropriate.

Pioglitazone Safety Considerations That Affect Coverage Decisions

Insurance coverage decisions for pioglitazone are informed by its safety profile. The FDA added a boxed warning for congestive heart failure risk in 2007, and in 2011 added a safety communication about a potential association with bladder cancer based on observational data (13).

Subsequent data have been more reassuring regarding bladder cancer. A 2020 meta-analysis of 26 studies published in BMJ Open found no statistically significant association between pioglitazone use and bladder cancer incidence (OR 1.07, 95% CI 0.99 to 1.15) (14). The FDA updated its communication in 2016 to note that the evidence was inconclusive, and it did not restrict prescribing.

The heart failure warning remains clinically relevant. Pioglitazone causes fluid retention through renal sodium reabsorption mediated by PPARγ activation in the collecting duct. The PROactive trial reported heart failure hospitalization in 5.7% of pioglitazone-treated patients versus 4.1% on placebo (7)). Prescribers should avoid pioglitazone in patients with NYHA class III or IV heart failure.

Some payers require attestation that the patient does not have heart failure before approving pioglitazone, even at the generic tier. This is a soft clinical edit, not a prior authorization, and is resolved by the prescriber confirming the indication and contraindication check at the point of prescribing.

Step-by-Step: Getting Pioglitazone at the Lowest Possible Cost

For patients and prescribers looking to minimize out-of-pocket spending on pioglitazone, the sequence below covers every major avenue.

First, confirm that the prescription is written for generic pioglitazone, not brand Actos. If the prescription already says "pioglitazone," the pharmacy will automatically dispense the generic.

Second, check your insurance formulary. Call the number on the back of your insurance card or log into your plan's online portal. Generic pioglitazone should appear on Tier 1. If it does not, ask about a formulary exception.

Third, compare cash prices at pharmacies near you using GoodRx, RxSaver, or Cost Plus Drugs (Mark Cuban's pharmacy). A 30-day supply of pioglitazone 30 mg can be purchased for $3 to $9 with a free discount coupon, often cheaper than your insurance copay.

Fourth, if uninsured and income-qualified, apply for the Takeda Help at Hand program through your prescriber's office. Processing takes 4 to 6 weeks, so request a 30-day bridge supply from your physician or a community health center while the application is pending.

Fifth, check eligibility for Extra Help (Medicare Low-Income Subsidy) if you are on Medicare. This program reduces Part D premiums and copays, and for pioglitazone, can reduce copays to $0 (9).

Patients filling pioglitazone at Walmart's $4 generic price or through a 340B pharmacy may find that paying cash is cheaper than using insurance. This is legal and common. The pharmacist can run both the insurance claim and the cash price and charge whichever is lower.